CRT’s close working relationship with Cancer Research UK’s Drug Development Office (DDO) facilitates clinical development of novel therapeutic agents. To date, DDO have taken in excess of 100 novel agents first into man of which five have been launched onto the market.

Activities of the DDO include:

• Scale-up production and manufacture of agents for clinical trials
• Non-clinical safety studies
• Sponsorship of Phase I and Phase II clinical trials

The DDO comprises several teams who directly oversee each stage of an early phase clinical trial. One such team is the CRT and Cancer Research UK joint initiative – Clinical Development Partnerships (CDP).

This initiative targets leading biotechnology and pharmaceutical companies with large pipelines that are forced to prioritise the agents taken into clinical development. CDP seeks to manage and support early-stage clinical trials bringing new life to deprioritised anti-cancer agents. Since its inception in 2006, CDP has successfully entered into five collaboration agreements with industry.

For more information please contact CRT

+44 (0) 20 3469 6300 enquiries@cancertechnology.com